2015
Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking
Falcone M, Bernardo L, Ashare RL, Hamilton R, Faseyitan O, McKee SA, Loughead J, Lerman C. Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking. Brain Stimulation 2015, 9: 191-196. PMID: 26572280, PMCID: PMC4789149, DOI: 10.1016/j.brs.2015.10.004.Peer-Reviewed Original ResearchConceptsTranscranial direct current stimulationDorsolateral prefrontal cortexLeft dorsolateral prefrontal cortexActive transcranial direct current stimulationMA anodal stimulationAnodal stimulationSmoking cessation treatmentSmoking behavior changeSelf-reported smokingDirect current stimulationSecondary outcomesCessation treatmentWashout periodFirst cigaretteCigarette cravingOvernight abstinenceTDCS sessionsSmoking sessionCigarette consumptionSmokingTherapeutic potentialCurrent stimulationPrefrontal cortexCognitive control circuitsCathodal stimulation
2012
Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work
2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTX
2006
Modeling the effect of alcohol on smoking lapse behavior
McKee SA, Krishnan-Sarin S, Shi J, Mase T, O’Malley S. Modeling the effect of alcohol on smoking lapse behavior. Psychopharmacology 2006, 189: 201-210. PMID: 17013640, PMCID: PMC2862311, DOI: 10.1007/s00213-006-0551-8.Peer-Reviewed Original ResearchConceptsFirst cigaretteSelf-administration sessionsNovel human laboratory modelPoor smoking cessation outcomesSmoking cessation outcomesSmoking lapse behaviorHuman laboratory modelEffects of alcoholSecondary outcomesAlcohol drinkersLapse behaviorMore cigarettesNicotine withdrawalCessation outcomesRisk factorsDaily smokersSubsequent smokingTobacco cravingPlacebo beverageTobacco relapseSmoking sessionHeavy social drinkersPriming drinkAlcohol consumptionAlcohol use